Nature Communications (Apr 2024)
VC-resist glioblastoma cell state: vessel co-option as a key driver of chemoradiation resistance
- Cathy Pichol-Thievend,
- Oceane Anezo,
- Aafrin M. Pettiwala,
- Guillaume Bourmeau,
- Remi Montagne,
- Anne-Marie Lyne,
- Pierre-Olivier Guichet,
- Pauline Deshors,
- Alberto Ballestín,
- Benjamin Blanchard,
- Juliette Reveilles,
- Vidhya M. Ravi,
- Kevin Joseph,
- Dieter H. Heiland,
- Boris Julien,
- Sophie Leboucher,
- Laetitia Besse,
- Patricia Legoix,
- Florent Dingli,
- Stephane Liva,
- Damarys Loew,
- Elisa Giani,
- Valentino Ribecco,
- Charita Furumaya,
- Laura Marcos-Kovandzic,
- Konstantin Masliantsev,
- Thomas Daubon,
- Lin Wang,
- Aaron A. Diaz,
- Oliver Schnell,
- Jürgen Beck,
- Nicolas Servant,
- Lucie Karayan-Tapon,
- Florence M. G. Cavalli,
- Giorgio Seano
Affiliations
- Cathy Pichol-Thievend
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Oceane Anezo
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Aafrin M. Pettiwala
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Guillaume Bourmeau
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Remi Montagne
- Institut Curie, PSL University
- Anne-Marie Lyne
- Institut Curie, PSL University
- Pierre-Olivier Guichet
- Université de Poitiers, CHU Poitiers, ProDiCeT
- Pauline Deshors
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Alberto Ballestín
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Benjamin Blanchard
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Juliette Reveilles
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Vidhya M. Ravi
- Department of Neurosurgery, Medical Center - University of Freiburg
- Kevin Joseph
- Department of Neurosurgery, Medical Center - University of Freiburg
- Dieter H. Heiland
- Department of Neurosurgery, Medical Center - University of Freiburg
- Boris Julien
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Sophie Leboucher
- Histology Facility, Institut Curie
- Laetitia Besse
- Institut Curie, PSL University, Université Paris-Saclay, CNRS UMS2016, INSERM US43, Multimodal Imaging Center
- Patricia Legoix
- Institut Curie, PSL University, ICGex Next-Generation Sequencing Platform
- Florent Dingli
- Institut Curie, PSL University, CurieCoreTech Spectrométrie de Masse Protéomique
- Stephane Liva
- Institut Curie, PSL University
- Damarys Loew
- Institut Curie, PSL University, CurieCoreTech Spectrométrie de Masse Protéomique
- Elisa Giani
- Department of Biomedical Sciences, Humanitas University
- Valentino Ribecco
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Charita Furumaya
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Laura Marcos-Kovandzic
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- Konstantin Masliantsev
- Université de Poitiers, CHU Poitiers, ProDiCeT
- Thomas Daubon
- Université Bordeaux, CNRS, IBGC, UMR5095
- Lin Wang
- Department of Computational and Quantitative Medicine, Hematologic Malignancies Research Institute and Beckman Research Institute, City of Hope
- Aaron A. Diaz
- Department of Neurological Surgery, University of California, San Francisco
- Oliver Schnell
- Department of Neurosurgery, Medical Center - University of Freiburg
- Jürgen Beck
- Department of Neurosurgery, Medical Center - University of Freiburg
- Nicolas Servant
- Institut Curie, PSL University
- Lucie Karayan-Tapon
- Université de Poitiers, CHU Poitiers, ProDiCeT
- Florence M. G. Cavalli
- Institut Curie, PSL University
- Giorgio Seano
- Institut Curie, INSERM U1021, CNRS UMR3347, Tumor Microenvironment Lab, Paris-Saclay University
- DOI
- https://doi.org/10.1038/s41467-024-47985-z
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 27
Abstract
Abstract Glioblastoma (GBM) is a highly lethal type of cancer. GBM recurrence following chemoradiation is typically attributed to the regrowth of invasive and resistant cells. Therefore, there is a pressing need to gain a deeper understanding of the mechanisms underlying GBM resistance to chemoradiation and its ability to infiltrate. Using a combination of transcriptomic, proteomic, and phosphoproteomic analyses, longitudinal imaging, organotypic cultures, functional assays, animal studies, and clinical data analyses, we demonstrate that chemoradiation and brain vasculature induce cell transition to a functional state named VC-Resist (vessel co-opting and resistant cell state). This cell state is midway along the transcriptomic axis between proneural and mesenchymal GBM cells and is closer to the AC/MES1-like state. VC-Resist GBM cells are highly vessel co-opting, allowing significant infiltration into the surrounding brain tissue and homing to the perivascular niche, which in turn induces even more VC-Resist transition. The molecular and functional characteristics of this FGFR1-YAP1-dependent GBM cell state, including resistance to DNA damage, enrichment in the G2M phase, and induction of senescence/stemness pathways, contribute to its enhanced resistance to chemoradiation. These findings demonstrate how vessel co-option, perivascular niche, and GBM cell plasticity jointly drive resistance to therapy during GBM recurrence.